Abstract
Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7499-7503 |
| Number of pages | 5 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 79 |
| Issue number | 23 I |
| DOIs | |
| State | Published - Dec 1 1982 |
Fingerprint
All Science Journal Classification (ASJC) codes
- General
Cite this
}
Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease. / Stetler, D. A.; Rose, K. M.; Wenger, M. E.; Berlin, C. M.; Jacob, S. T.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 79, No. 23 I, 01.12.1982, p. 7499-7503.Research output: Contribution to journal › Article
TY - JOUR
T1 - Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease
AU - Stetler, D. A.
AU - Rose, K. M.
AU - Wenger, M. E.
AU - Berlin, C. M.
AU - Jacob, S. T.
PY - 1982/12/1
Y1 - 1982/12/1
N2 - Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.
AB - Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.
UR - http://www.scopus.com/inward/record.url?scp=0020452231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020452231&partnerID=8YFLogxK
U2 - 10.1073/pnas.79.23.7499
DO - 10.1073/pnas.79.23.7499
M3 - Article
C2 - 6961426
AN - SCOPUS:0020452231
VL - 79
SP - 7499
EP - 7503
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
SN - 0027-8424
IS - 23 I
ER -